Lancora is commonly used across domains where additional symptomatic support is needed for conditions involving heightened physiological stress on the heart.

The medication is generally applied in key clinical scenarios, including for supportive symptom management in chronic heart failure (HFrEF) and for easing symptoms of chronic stable angina pectoris. It is also commonly used as an alternative when other rate-lowering options are considered less appropriate, and for select pediatric patients with stable symptomatic heart failure due to dilated cardiomyopathy.

Supportive Relief

Lancora is generally used in conditions characterized by periods of heightened symptoms of chronic heart failure where the heart is experiencing functional stress and the patient has an elevated resting heart rate (typically 70 bpm). The primary benefit is providing supportive therapy that helps ease the overall symptom burden of the condition and assists with maintaining functional stability.

“It assists with managing symptoms that may become intense, such as the overall burden of anginal discomfort.”

This focus on symptomatic improvement means Lancora helps manage the physical discomfort and strain associated with recurring chest pain, contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Elevated Cardiac Rate (Applied in situations involving a high resting heart rate to ease symptomatic burden and supports general well-being during symptomatic phases.)

Regulatory References

1. European Medicines Agency Product Information

Eligibility for Lancora (Ivabradine)

Lancora’s use is strictly defined by the patient’s clinical status and other medical conditions, as specified in regulatory labeling.

Approved Populations:

• Adults in sinus rhythm with a resting heart rate 70 bpm for chronic stable angina or chronic heart failure.
• Pediatric patients (aged 6 months and older) for specific types of stable symptomatic heart failure.

---

Absolute Contraindications (Must Not Use):

• Patients with a resting heart rate below 60 bpm prior to treatment, or below 70 bpm as specified by some European labels.
• Patients with severe hepatic impairment or severe hypotension (< 90/50 mmHg).
• Patients with acute decompensated heart failure, cardiogenic shock, or conditions like sick sinus syndrome or third-degree AV block.
• Patients who are pacemaker-dependent or are using strong CYP3A4 inhibitors (e.g., ketoconazole, diltiazem).
• Pregnant or breastfeeding women. Females of reproductive potential must use effective contraception.

---

Use Restrictions and Considerations:

• The medicine is not recommended for patients with second-degree AV block or those with atrial fibrillation.
• Caution is advised in patients with moderate hepatic impairment and in older adults aged 75 years.

Interactions with other medicines and products

The simultaneous use of Lancora (ivabradine) with certain other medicines or products is restricted due to the potential for significant interaction-related risks, including increased exposure to the drug or additive effects on heart rate.

Lancora is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong CYP3A4 inhibitors, such as certain azole antifungals (e.g., ketoconazole) and HIV protease inhibitors (e.g., nelfinavir), is contraindicated as it substantially increases drug levels and can exacerbate bradycardia (slow heart rate) or conduction disturbances.

The simultaneous use of Lancora with the heart rate-reducing calcium channel blockers Verapamil and Diltiazem is also contraindicated. This restriction is due to both the inhibitory effect of these agents on CYP3A4 and their additive effect on heart rate.

Co-administration with CYP3A4 inducers, including rifampicin, phenytoin, barbiturates, and the herbal product St. John's Wort, is generally avoided as they can decrease the drug's plasma concentration and effectiveness. The risk of bradycardia is increased when Lancora is combined with other negative chronotropes (medicines that slow the heart rate), such as digoxin, amiodarone, or beta-blockers; heart rate should be closely monitored in such combinations.

Patients should also avoid consuming grapefruit juice during treatment due to its potential to significantly increase the drug’s blood levels and effects.

How Lancora Works

Lancora is a selective modulator that acts on defined primary receptor systems located in central and peripheral pathways. Its mechanism of action involves high-affinity binding to the target receptors, initiating a conformational change that adjusts the rate of signal transduction. This molecular interaction reduces the input from overactive receptor systems that drive dysregulated activity in the affected tissue.

Following receptor engagement, Lancora operates within specific signal transduction cascades, influencing secondary messengers and their intracellular effects. This targeted pathway modulation limits the propagation of excessive signaling to downstream cellular targets, thereby supporting the establishment of a more regulated physiological state within the affected system. The drug's influence on core regulatory pathways dictates its overall pharmacodynamic profile.

How to Use Lancora

Lancora (Ivabradine) is administered exclusively via the oral route, available as film-coated tablets or an oral solution in specific regions. The application of this medicine is governed by a structured, standardized protocol, covering initial dosing, frequency, meal relation, and long-term adjustments.

---

Official Administration Guidelines

Feature	Official Labeled Instruction
Route & Form	Oral; film-coated tablets (5 mg and 7.5 mg) or oral solution.
Dosing Schedule	Standard adult starting dose is 5 mg twice daily (BID). Maximum dose is 7.5 mg twice daily.
Timing in relation to meals	Must be taken with food (with meals) in the morning and evening.
Older Adult Rule	For patients 75 years of age or older, a reduced starting dose of 2.5 mg twice daily should be considered.
Titration Protocol	Dose adjustment is implemented after two to four weeks of treatment, with the goal of achieving a resting heart rate between 50 and 60 beats per minute.
Missed-Dose Rule	If a dose is missed, the dose should be skipped; the next dose must be taken at the regularly scheduled time, and the dose must not be doubled.

---

Procedural Structure

The entire regimen is intended for use as part of a chronic, long-term treatment plan. The administration is initiated with the specified starting quantity, followed by a mandatory, time-dependent adjustment phase. This protocol defines the precise timing, the divided daily doses, and the procedural endpoint necessary for the standardized application of the medicine.

Research evidence / Overview of studies for Lancora (Ivabradine)

Evidence for Use in Chronic Heart Failure (HFrEF)

This part will summarize the findings from large, randomized controlled trials (RCTs) and systematic reviews focused on adult patients with reduced heart function and an elevated heart rate. It will detail the specific cardiovascular outcomes and patient-reported measures (like quality of life) that these studies examined over the long term.

Research was conducted on adults with chronic heart failure. Research primarily relied on large-scale, international Randomized Controlled Trials (RCTs) against placebo, with median follow-up durations extending over approximately two years. These trials focused on patients who had a confirmed reduction in heart pumping ability (ejection fraction), were in a normal heart rhythm, and had a high resting heart rate, typically 70 beats per minute or more.

Trials described patterns related to a reduced rate of hospitalization for heart failure in the studied population subgroup with a high baseline heart rate. Data also show patterns related to overall mortality rates and the rate of the combined serious event endpoint. However, the evidence regarding an effect on overall survival in the broader heart failure population remains limited. The reported patterns apply only to the populations studied, meaning the clearest observations were in patients who already had a resting heart rate of 70 bpm or higher.

Evidence for Use in Chronic Stable Angina Pectoris

This area will outline the research structure, including placebo-controlled and active-comparator trials, that investigated the effects of Lancora on exercise tolerance, the frequency of chest pain episodes, and the need for acute symptom relief medication in adults with stable angina. It will also note the findings related to major cardiovascular event endpoints in this patient group.

Short-term trials documented measurements related to symptomatic changes, noting changes in the frequency of reported angina attacks and the need for nitrate use. Observed patterns in exercise testing described measurements related to changes in time to limiting angina compared to placebo. However, assessments of the long-term major cardiovascular event endpoint did not change notably in the overall stable coronary artery disease population. Long-term outcomes are not fully established in all contexts.

What is Still Uncertain About Lancora's Evidence

The overall evidence landscape, while defined by large trials, has specific areas where certainty remains low. Long-term outcomes are not fully established in several key areas, particularly regarding the effect on major cardiovascular events in the general stable angina population. Furthermore, the findings for both heart failure and angina apply only to the populations studied, notably those with a high baseline heart rate, and evidence quality varies across studies when analyzing specific subgroups. Overall, the research provides context but not individual predictions for all patients.

Key Studies & References Ivabradine Study in Pediatric Patients With Symptomatic Heart Failure Due to Dilated Cardiomyopathy (Study CL2-090)

Common questions about Lancora (FAQ)

---

Q: What happens if I forget to take a dose of Lancora?

If a dose of Lancora is missed, official patient information advises that the missed dose should be skipped entirely. The next dose is typically taken at the regular, scheduled time. According to official guidelines, the dose should not be doubled to make up for the missed one.

---

Q: Which other medicines are completely restricted from being taken with Lancora?

Regulatory documents state that Lancora is contraindicated (meaning it must not be used) with several other medicines. This includes drugs classified as strong CYP3A4 inhibitors (such as certain antifungals) and the heart rate-reducing calcium channel blockers Verapamil and Diltiazem. The co-administration of Lancora with these agents may increase the risk of serious side effects.

---

Q: Is Lancora used for blood pressure or to help with cholesterol?

Lancora is indicated by regulators primarily for managing chronic heart failure and stable angina. While official product information notes restrictions for patients with very low blood pressure (hypotension), its primary mechanism is a controlled reduction in heart rate, and it is not formally indicated for treating high blood pressure or lowering cholesterol.

---

Q: How long does it take for Lancora to start working (to lower my heart rate)?

Official pharmacological data indicates that the active ingredient in Lancora typically reaches its peak concentration in the blood approximately one hour after it is taken. Regulatory guidelines instruct that a dose adjustment, if necessary, is typically performed after the first two weeks of treatment. This assessment period is part of the standardized process for evaluating the medicine’s effect on the heart rate.

---

Q: What specific type of doctor typically prescribes Lancora?

Because Lancora is used to treat specific, serious cardiovascular conditions, the medicine is often prescribed or initiated by a doctor with specialized experience in managing these disorders. This often includes specialists, such as cardiologists, who are experienced in treating these complex conditions.

---

Q: Can I crush, chew, or split the Lancora tablet?

The official product information states that the 5 mg Lancora film-coated tablet is manufactured to be scored and is breakable. This feature is included to facilitate dose flexibility for various patient needs, as determined by a healthcare provider.

How to Store and Dispose of Lancora (Ivabradine)

The storage and disposal requirements for Lancora (ivabradine) are defined by official regulatory labeling to ensure product stability and safety.

Required Storage Conditions

Lancora must be stored at controlled room temperature, specifically maintained between 68 F and 77 F (20 C to 25 C), with short excursions permitted between 59 F and 86 F (15 C to 30 C). The medication must be kept in its closed container and protected from freezing, excessive heat, moisture, and direct light.

Child Safety and Disposal

It is mandatory to store Lancora out of the sight and reach of children.

Patients should not keep unused or outdated medicine. Official instructions require that individuals ask a healthcare professional or pharmacist how to properly dispose of any medicine that is no longer needed.